Real-World Cohort Study Initiated to Assess Oral Semaglutide Effectiveness in Thai Type 2 Diabetes Patients

Effective management of Type 2 Diabetes (T2D) remains a global health challenge, particularly in diverse populations where lifestyle factors and genetic predispositions can influence treatment responses. Current standard-of-care often involves a combination of lifestyle modifications and pharmacotherapy, but achieving sustained glycemic control and body weight reduction can be difficult. GLP-1 receptor agonists have emerged as highly effective agents, but their injectable nature can be a barrier for some patients. Oral semaglutide offers a convenient alternative, and understanding its real-world efficacy in specific ethnic populations like Thai patients is crucial to address existing treatment gaps and optimize patient outcomes.

This retrospective, multi-centre cohort study included 195 adult patients with Type 2 Diabetes in Thailand who initiated treatment with oral semaglutide. Data on eligible patients were collected via electronic medical records or paper-format chart review. The primary objective was to assess the effectiveness of oral semaglutide on glycemic control (e.g., HbA1c) and body weight control. The total study duration for individual patients was six months from baseline, with an optional 12-month follow-up visit to gather additional long-term data on treatment outcomes.

The provided abstract and domain context describe the study's design and objectives but do not report specific findings regarding oral semaglutide's effectiveness on glycemic control or body weight in this Thai cohort. The study aims to collect data over six months, with an optional 12-month visit, to assess these outcomes. Therefore, no quantitative results, p-values, or fold-changes are available from the provided information.